FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease

29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...

Read more →

Recommendations made by the PBAC – July 2021

20 August 2021 - Recommendations made by the PBAC in July 2021 relating to the listing of medicines on the PBS ...

Read more →

TGA provisionally approves GlaxoSmithKline's COVID-19 treatment sotrovimab (Xevudy)

20 August 2021 - Today, the Therapeutic Goods Administration granted provisional approval to GSK for its COVID-19 treatment - sotrovimab ...

Read more →

Astellas receives European Commission approval for first in class Evrenzo (roxadustat) for adult patients with symptomatic anaemia of chronic kidney disease

20 August 2021 - Roxadustat is the first orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor available for adult patients with anaemia ...

Read more →

CADTH welcomes transfer of drug safety and effectiveness network

13 August 2021 - CADTH welcomes today’s announcement by the Canadian Institutes of Health Research and Health Canada that they ...

Read more →

NICE’s health technology assessment methods and processes to be evaluated

19 August 2021 - NICE has launched a public consultation on proposed changes to the way it develops recommendations across ...

Read more →

Booster shots ‘make a mockery of vaccine equity,’ the WHO’s Africa director says

19 August 2021 - The Africa director at the World Health Organization, Dr. Matshidiso Moeti, criticized the decisions by some ...

Read more →

Contradicting WHO, US advises adults to receive COVID-19 boosters

19 August 2021 - The Biden administration is advising all American adults to receive a COVID-19 booster shot after accumulating ...

Read more →

EMA validates Gilead’s marketing authorisation application for lenacapavir, an investigational, long-acting capsid inhibitor for the treatment of HIV-1 in people with limited therapy options

19 August 2021 - EMA MAA validation follows submission of NDA for Lenacapavir to the U.S. FDA. ...

Read more →

EndoPredict for breast cancer - the company chose not to participate with data

19 August 2021 - In November 2020, Myriad Genetics chose to refrain from participating in a health economic assessment of EndoPredict.  ...

Read more →

Senhwa's silmitasertib receives US FDA fast track designation for the treatment of recurrent sonic hedgehog driven medulloblastoma

19 August 2021 - Senhwa Biosciences today announced that the US FDA has granted fast track designation for silmitasertib, a highly ...

Read more →

Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy

19 August 2021 - Based on cancer biomarkers, the first-of-its-kind VENTANA MMR RxDx Panel helps determine which solid tumour patients may ...

Read more →

NICE recommends first treatment for rare blood disorder

19 August 2021 - People with a rare blood disorder have access to a new treatment following draft guidance from NICE. ...

Read more →

TGA approves name change of COVID-19 Vaccine AstraZeneca to Vaxzevria

19 August 2021 - The Therapeutic Goods Administration has approved AstraZeneca's submission to change the name of its COVID-19 Vaccine ...

Read more →

BeiGene announces acceptance by Swissmedic of marketing authorisation application for Brukinsa (zanubrutinib) in Waldenström’s macroglobulinaemia

18 August 2021 - BeiGene announced that Swissmedic has accepted the marketing authorisation application for Brukinsa, a treatment option for adult ...

Read more →

COVID-19 vaccine weekly safety report (19 August 2021)

19 August 2021 - To 15 August 2021, approximately 15.3 million vaccine doses have been given in Australia – 9.9 million ...

Read more →